Researchers discover brain pathway that dissociates opioid addiction from analgesia

February 12, 2018, The Mount Sinai Hospital
Targeting RGSz1 allows the dissociation of opioid addiction from analgesia and prevents tolerance by promoting beta-catenin action. Credit: Thalia Chantziara

A newly identified protein can be manipulated to make opioid painkillers effective at lower doses while also muting the reward mechanism that leads to addiction, Mount Sinai researchers have found.

The , RGSz1 (Regulator of G protein signaling z1), which is expressed in brain regions that mediate analgesic responses, is part of an intracellular network that controls the pain-relieving effects of analgesics like morphine, fentanyl, and methadone without increasing the risk of reward or dependence, according to the study conducted in mouse models at the Icahn School of Medicine at Mount Sinai and published February 12 in Proceedings of the National Academy of Sciences. The mechanisms uncovered in this study may provide novel avenues for pharmacological interventions that can be used to optimize the actions of opioid medications, leading to safer and less addictive treatments.

Opioids are powerful analgesics, but when they are used long-term, they promote dependence and can easily transition to addiction. Patients who receive opioids for chronic pain require higher amounts of the drug over time as they develop analgesic tolerance. The need for higher amounts not only results in severe and often life-threatening adverse effects, but it also increases the risk for dependence and addiction. Amidst the current opioid crisis in the United States, there is an immediate need to develop novel therapeutic interventions for safer and more efficient analgesics.

The development of safer opioids is challenging because are expressed throughout the brain and not just in the cells mediating . The Mount Sinai research team targeted an intracellular network that controls the actions of opioids primarily in the periaqueductal gray, a brain region that plays a critical role in analgesic responses. Using genetic mouse models for global or brain region-targeted manipulation of RGSz1 expression, Mount Sinai researchers identified RGSz1 as a negative modulator of opioid analgesia, and a tolerance-promoting factor. Mice that lacked the gene responsible for encoding RGSz1 (RGSz1 knockout mice) responded to significantly lower doses of opioids to achieve pain relief. Furthermore, when RGSz1 activity was blocked, opioids were less rewarding, providing further evidence that RGSz1-controlled pathways may be targeted to optimize the therapeutic actions of opioids.

"Our discovery that RGSz1 and RGSz1 regulated pathways can be targeted to promote analgesia is very exciting because it enables us to develop strategies for the use of low opioid doses for pain relief," says Venetia Zachariou, PhD, Associate Professor in the Fishberg Department of Neuroscience, the Department of Pharmacological Sciences, The Friedman Brain Institute, and The Addiction Institute, Icahn School of Medicine at Mount Sinai.

Additionally, the research team discovered that RGSz1 competes with another RGS protein, Axin 2, and this competition controls the function of the protein β-catenin. β-catenin plays an important role in opioid actions by promoting the expression of genes that counteract the maladaptive changes associated with analgesic tolerance. This is another factor uncovered in this study that provides insight about the cellular and molecular pathways that mediate the actions of opioids in specific brain regions or cell types, which is essential for the development of safer therapeutics for analgesia or addiction.

"RGSz1 is expressed only in subsets of neurons that mediate opioid actions. The actions of opioids in addiction-related networks are mediated by distinct RGS proteins. We are now screening currently prescribed opioids as well as new compounds to determine their abuse potential and analgesic efficacy based on the RGS protein they activate. That knowledge will be power in the fight against this deadly opioid epidemic," says Dr. Zachariou.

Explore further: Key signaling protein associated with addiction controls the actions of oxycodone on pain

More information: Sevasti Gaspari el al., "Suppression of RGSz1 function optimizes the actions of opioid analgesics by mechanisms that involve the Wnt/β-catenin pathway," PNAS (2018). www.pnas.org/cgi/doi/10.1073/pnas.1707887115

Related Stories

Key signaling protein associated with addiction controls the actions of oxycodone on pain

January 17, 2017
RGS9-2, a key signaling protein in the brain known to play a critical role in the development of addiction-related behaviors, acts as a positive modulator of oxycodone reward in both pain-free and chronic pain states, according ...

Opioid abuse initiates specific protein interactions in neurons in brain's reward system

February 24, 2014
Identifying the specific pathways that promote opioid addiction, pain relief, and tolerance are crucial for developing more effective and less dangerous analgesics, as well as developing new treatments for addiction. Now, ...

Safer opioid drugs could treat pain and save lives

December 5, 2017
Opioid drugs are the most widely prescribed and effective type of pain medication. But they are highly addictive and have some unpleasant and potentially deadly side effects.

How to avoid opioid addiction after surgery

January 30, 2018
(HealthDay)—Following surgery, many patients head home with prescriptions for 30 or more opioid painkillers—enough to trigger addiction, warns a leading group of anesthesiologists.

Separating side effects could hold key for safer opioids

November 16, 2017
Opioid pain relievers can be extremely effective in relieving pain, but can carry a high risk of addiction and ultimately overdose when breathing is suppressed and stops. Scientists have discovered a way to separate these ...

Understanding pain exacerbation with opioid use

February 5, 2018
A new study published in JNeurosci advances understanding of how the potent opioid analgesic fentanyl can increase pain sensitivity in animals. These findings could inform the development of treatments for chronic pain that ...

Recommended for you

A peek into the interplay between sleep and wakefulness

July 20, 2018
Sleep is an autonomic process and is not always under our direct, voluntary control. Awake or asleep, we are basically under the regulation of two biological processes: sleep homeostasis, commonly known as 'sleep pressure', ...

Paralyzed mice with spinal cord injury made to walk again

July 19, 2018
Most people with spinal cord injury are paralyzed from the injury site down, even when the cord isn't completely severed. Why don't the spared portions of the spinal cord keep working? Researchers at Boston Children's Hospital ...

Neural inflammation plays critical role in stress-induced depression

July 19, 2018
A group of Japanese researchers has discovered that neural inflammation caused by the innate immune system plays an unexpectedly important role in stress-induced depression. This insight could potentially lead to the development ...

Scientists uncover the role of a protein in production and survival of myelin-forming cells

July 19, 2018
The nervous system is a complex organ that relies on a variety of biological players to ensure daily function of the human body. Myelin—a membrane produced by specialized glial cells—plays a critical role in protecting ...

Understanding the neuroscience of binge drinking

July 19, 2018
A new study from researchers at Columbia University Irving Medical Center found that binge drinking impairs working memory in the adolescent brain. The study, in mice, explains why teenagers who binge drink are 15 times more ...

Neurons can carry more than one signal at a time

July 18, 2018
Back in the early days of telecommunications, engineers devised a clever way to send multiple telephone calls through a single wire at the same time. Called time-division multiplexing, this technique rapidly switches between ...

3 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

JamesG
5 / 5 (1) Feb 12, 2018
And 20 years from now we may see some actual drugs related to this. It's frustrating how long it takes to get studies done and get results. I'm suspicious researchers lose the sense of urgency we need to get these drugs to help people. Not saying they don't care, just that they get caught up in the bureaucracy.
Anonym216579
not rated yet Feb 12, 2018
Exactly. There is all sorts of awesome stuff being researched that people need now but it will be decades before its available. Its absolutely insane that they are taking away opiates and other great alternatives like kratom WITHOUT having any real comparable substitute for chronic pain sufferers.
sascoflame
not rated yet Feb 13, 2018
It is negative reinforcement, not pleasure that causes addiction. Escaping from pain is the most powerful reinforcement.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.